GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Meropenem

Merrem

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

Nebraska Medicine - meropenem by CVVHD flow

Product / population
Adults; IV meropenem, source PDF page 7.
Renal measure
CVVHD dialysate flow, with indication/MIC stratification.

Dosing / renal protocol and limits

Standard CVVHD treatment: 1 g IV load then 500 mg every 6 hours at dialysate flow 1-4 L/hour. For meningitis, cystic fibrosis or MIC 4, the guide uses 2 g loading, then 2 g every 12 hours at 1 L/hour or every 8 hours at 2-4 L/hour. Do not use the anephric non-CRRT column while clearance is being provided by CVVHD.

Source revision: 2023 CRRT/PIRRT reference. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Professional guidance

UCSF - meropenem: indication-specific renal doses

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Professional guidance

Nebraska Medicine - meropenem by CVVHD flow

Adults; IV meropenem, source PDF page 7.

Renal method: CVVHD dialysate flow, with indication/MIC stratification.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The non-label dialysis regimens are separate GlobalRPh reference material, not manufacturer instructions. No renal-adjusted meningitis regimen is inferred.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/meropenem/

Usual Dosing (Adults)

Usual: 1 g IV every 8 hours. Complicated skin/skin-structure infection: 500 mg every 8 hours. Intra-abdominal infection: 1 g every 8 hours. Meningitis: 2 g every 8 hours.

GRPH-meropenem-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl above 50 mL/min: no change. CrCl 26-50: usual 1 g every 12 hours, or 500 mg every 12 hours for UTI/skin infection. CrCl 10-25: usual 500 mg every 12 hours, or 250 mg every 12 hours for UTI/skin infection. CrCl below 10: usual 500 mg every 24 hours, or 250 mg every 24 hours for UTI/skin infection.

GRPH-meropenem-02 · Source section: Renal DosingRenal section finder

Hemodialysis

The source states that the package insert has inadequate information for hemodialysis and no peritoneal-dialysis experience. It then gives separate other-reference regimens: hemodialysis, 500 mg every 24 hours plus 500 mg after dialysis; peritoneal dialysis, 500 mg every 24 hours.

GRPH-meropenem-03 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

UCSF - meropenem: indication-specific renal doses

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

IV short-infusion regimens for renal bands >50 / 26-50 / 10-25 / <10 mL/min:

  • Standard: 1 g every 8 hours / 1 g every 12 hours / 500 mg every 12 hours / 500 mg daily.
  • Meningitis or cystic fibrosis: 2 g every 8 hours / 2 g every 12 hours / 1 g every 12 hours / 1 g daily.

IHD: standard 500 mg initially, then every evening; meningitis/cystic fibrosis 1 g initially, then every evening.

CVVHD: standard 1 g every 8 hours; meningitis/cystic fibrosis 2 g every 12 hours. Discuss flow exceeding 2 L/hour with ID pharmacy.

Selected extended infusion uses a 1 g loading dose over 30 minutes, with maintenance beginning 4 hours later. At renal function >50 / 26-50, standard maintenance is 1 g over 3 hours every 8 / 12 hours; meningitis/cystic fibrosis maintenance is 2 g at those intervals. Below 26, use short infusion. Meningitis extended-infusion evidence is limited.

RDM30-002-meropenem-1 · Source locator: UCSF - meropenem: indication-specific renal doses; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/meropenem
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
58f2512194729f4eb0d26cdadc465a2322524b4b9ed22f538e44c5cb87ebd2fc
Professional

Nebraska Medicine - meropenem by CVVHD flow

Open original reference

Open / share this exact local source

University of Nebraska Medical Center / Nebraska Medicine · Adults; IV meropenem, source PDF page 7.

Renal method: CVVHD dialysate flow, with indication/MIC stratification.
Source date: 2023 CRRT/PIRRT reference.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Standard CVVHD treatment: 1 g IV load then 500 mg every 6 hours at dialysate flow 1-4 L/hour. For meningitis, cystic fibrosis or MIC 4, the guide uses 2 g loading, then 2 g every 12 hours at 1 L/hour or every 8 hours at 2-4 L/hour. Do not use the anephric non-CRRT column while clearance is being provided by CVVHD.

RDM30-063-meropenem-1 · Source locator: Nebraska Medicine - meropenem by CVVHD flow; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf
Retrieved
2026-09-05
Renal-function method
CVVHD dialysate flow, with indication/MIC stratification.
Source date/version
2023 CRRT/PIRRT reference.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e0d2da552e822d24394a878f7be4e5c1f934943b59462ace94e83390647e3302

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/meropenem/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
cc0cc71832660334c669df34ca8e632f101f878fdf5767dd31be07e0e92026ce
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report